NCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
Clinical Trials
19 trialsNCT05440786 2026-03-12
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06541262 2026-03-02
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT06709495 2026-02-19
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT04901702 2026-02-09
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT07092306 2025-07-29
A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT03359005 2022-11-01
Irinotecan and Temozolomide for Ewing Sarcoma
Peking University People's Hospital
Phase 2 Unknown
NCT02727387 2022-09-19
EW-2
Italian Sarcoma Group
Phase 2 Completed
NCT02044120 2021-01-12
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 1 Completed
NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT01313884 2017-11-24
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Stanford University
Phase 2 Terminated
NCT00492141 2012-08-02
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
M.D. Anderson Cancer Center
Phase 1/2 Completed